This protocol applies to patients with Type IV renal tubular acidosis in whom the established first-line regimen of loop diuretics combined with oral sodium bicarbonate did not sustain the required metabolic targets. It defines the structured next step for this specific failure scenario.
The preceding treatment line used loop diuretics combined with oral sodium bicarbonate (NaHCO₃) — with oral bicarbonate administered to maintain serum HCO₃⁻ within the normal range in patients whose bicarbonate fell below the treatment threshold.
Escalation to this protocol is indicated when that approach fails to achieve maintenance of serum bicarbonate in the normal range and meaningful reduction in serum potassium concentration.
The targets for this line include a meaningful reduction in serum potassium concentration and a measurable increase in serum bicarbonate concentration.
For patients with hyperkalemic type 4 RTA, there are newer K⁺-binding agents available (i.e., patiromer and sodium zirconium cyclosilicate [SZC]), which can be used to treat hyperkalemia and improve acidosis.
SZC has also been associated with significant increases in serum HCO₃⁻ concentrations by approximately 2 mmol/L versus placebo during the initial 48-h treatment period and 2–3 mmol/L during maintenance therapy for 1 month, regardless of CKD stage.